Compare MDBH & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MDBH | ATRA |
|---|---|---|
| Founded | 1997 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.7M | 37.6M |
| IPO Year | 2023 | 2014 |
| Metric | MDBH | ATRA |
|---|---|---|
| Price | $3.27 | $5.58 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 12.2K | ★ 711.8K |
| Earning Date | 11-13-2025 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.76 | ★ 1.97 |
| Revenue | $1,250,398.00 | ★ $151,930,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.38 | ★ $2.83 |
| Revenue Growth | N/A | ★ 51.27 |
| 52 Week Low | $3.11 | $4.20 |
| 52 Week High | $7.98 | $19.15 |
| Indicator | MDBH | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 42.26 | 30.29 |
| Support Level | $3.21 | $4.20 |
| Resistance Level | $3.48 | $5.19 |
| Average True Range (ATR) | 0.16 | 1.12 |
| MACD | -0.03 | -0.19 |
| Stochastic Oscillator | 9.93 | 9.94 |
MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries and focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The Company operates in two reportable segments: a broker dealer & intellectual property service, and the technology development segment. The broker dealer & intellectual property service segment, which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).